Literature DB >> 24574329

Association of serum C-reactive protein levels with lupus disease activity in the absence of measurable interferon-α and a C-reactive protein gene variant.

Helena Enocsson1, Christopher Sjöwall, Alf Kastbom, Thomas Skogh, Maija-Leena Eloranta, Lars Rönnblom, Jonas Wetterö.   

Abstract

OBJECTIVE: The type I interferon (IFN) system is important in the pathogenesis of systemic lupus erythematosus (SLE). We previously demonstrated an inhibitory effect of IFNα on interleukin-6 (IL-6)-induced C-reactive protein (CRP) in vitro, hypothetically explaining the poor correlation between disease activity and CRP levels in SLE. This study was undertaken to investigate disease activity, IL-6 levels, and CRP levels in relation to a CRP gene polymorphism and IFNα.
METHODS: Sera from 155 SLE patients and 100 controls were analyzed for CRP. Patients were genotyped for a CRP single-nucleotide polymorphism (rs1205) associated with low CRP levels. Serum IFNα and IL-6 levels were quantified by immunoassays. Clinical disease activity was assessed using the SLE Disease Activity Index 2000 (SLEDAI-2K).
RESULTS: CRP levels were increased in SLE patients compared to controls, but were not associated with SLEDAI-2K or IL-6 levels. However, exclusion of patients carrying at least one rs1205 minor allele revealed an association between disease activity and CRP levels (P = 0.005). We found a strong association between disease activity and CRP levels (P < 0.0005) when patients with measurable IFNα levels as well as the minor allele of rs1205 were excluded from the analysis. Similarly, when patients with elevated IFNα levels and/or the rs1205 polymorphism were excluded, IL-6 levels were associated with CRP levels.
CONCLUSION: The present study demonstrates that the serum IFNα level as well as the CRP genotype affect the CRP response in SLE patients. Lack of correlation between serum levels of CRP and disease activity could therefore be explained by activation of the type I IFN system and polymorphisms in the CRP gene.
Copyright © 2014 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24574329     DOI: 10.1002/art.38408

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  13 in total

Review 1.  Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for intervention.

Authors:  M Wigren; J Nilsson; M J Kaplan
Journal:  J Intern Med       Date:  2015-11       Impact factor: 8.989

2.  Interferon-α coincides with suppressed levels of pentraxin-3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 in vitro.

Authors:  L Wirestam; H Enocsson; T Skogh; M L Eloranta; L Rönnblom; C Sjöwall; J Wetterö
Journal:  Clin Exp Immunol       Date:  2017-03-31       Impact factor: 4.330

3.  Correlation of CRP genotypes with serum CRP levels and the risk of rheumatoid arthritis in Chinese Han population.

Authors:  Shanshan Liu; Ju Li; Yongsheng Li; Yan Liu; Kai Wang; Wenyou Pan
Journal:  Clin Rheumatol       Date:  2022-07-28       Impact factor: 3.650

4.  C-reactive protein (CRP) polymorphisms and haplotypes are associated with SLE susceptibility and activity but not with serum CRP levels in Mexican population.

Authors:  Yemil Atisha-Fregoso; Guadalupe Lima; Eduardo Carrillo-Maravilla; Rosalinda Posadas-Sánchez; Nonanzit Pérez-Hernández; Miguel Baños-Peláez; Alejandra Iturralde-Chávez; Nora Hernández-Díaz; Juan Jakez-Ocampo; José Manuel Rodríguez-Pérez; Gilberto Vargas-Alarcón; Luis Llorente; Juanita Romero-Díaz
Journal:  Clin Rheumatol       Date:  2018-03-20       Impact factor: 2.980

5.  C-reactive protein +1444CT (rs1130864) genetic polymorphism is associated with the susceptibility to systemic lupus erythematosus and C-reactive protein levels.

Authors:  Francieli Delongui; Marcell Allyson Batisti Lozovoy; Tatiana Mayiumi Veiga Iriyoda; Neide Tomimura Costa; Nicole Perugini Stadtlober; Daniela Frizon Alfieri; Tamires Flauzino; Isaias Dichi; Andréa Name Colado Simão; Edna Maria Vissoci Reiche
Journal:  Clin Rheumatol       Date:  2017-06-01       Impact factor: 2.980

6.  Longitudinal Evaluation of Lipoprotein Variables in Systemic Lupus Erythematosus Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profiles with Hydroxychloroquine Therapy.

Authors:  Laura Durcan; Deborah A Winegar; Margery A Connelly; James D Otvos; Laurence S Magder; Michelle Petri
Journal:  J Rheumatol       Date:  2016-02-01       Impact factor: 4.666

7.  Application of the 2012 Systemic Lupus International Collaborating Clinics classification criteria to patients in a regional Swedish systemic lupus erythematosus register.

Authors:  Anna Ighe; Örjan Dahlström; Thomas Skogh; Christopher Sjöwall
Journal:  Arthritis Res Ther       Date:  2015-01-10       Impact factor: 5.156

8.  Pronounced Diurnal Pattern of Salivary C-Reactive Protein (CRP) With Modest Associations to Circulating CRP Levels.

Authors:  Jonas Wetterö; Sarah von Löhneysen; Flordelyn Cobar; Margareta Kristenson; Peter Garvin; Christopher Sjöwall
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

9.  Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up.

Authors:  Satu Sinikka Pesickova; Romana Rysava; Martin Lenicek; Libor Vitek; Eliska Potlukova; Zdenka Hruskova; Eva Jancova; Eva Honsova; Jakub Zavada; Marten Trendelenburg; Vladimir Tesar
Journal:  Arthritis Res Ther       Date:  2015-12-24       Impact factor: 5.156

10.  Increased von Willebrand factor levels in patients with systemic lupus erythematosus reflect inflammation rather than increased propensity for platelet activation.

Authors:  Johannes C Nossent; Warren D Raymond; Gro Østli Eilertsen
Journal:  Lupus Sci Med       Date:  2016-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.